Development of physiology based pharmacokinetic model to predict the drug interactions of voriconazole and venetoclax
J Dong, S Liu, JM Rasheduzzaman, C Huang… - Pharmaceutical …, 2022 - Springer
Purpose Venetoclax (VEN), an anti-tumor drug that is a substrate of cytochrome P450 3A
enzyme (CYP3A4), is used to treat leukemia. Voriconazole (VCZ) is an antifungal …
enzyme (CYP3A4), is used to treat leukemia. Voriconazole (VCZ) is an antifungal …
Influences of C-reactive protein on the pharmacokinetics of voriconazole in relation to the CYP2C19 genotype: A population pharmacokinetics analysis
L Jing, Y Jiang, N Hu - Frontiers in Pharmacology, 2024 - frontiersin.org
Voriconazole is a broad-spectrum triazole antifungal agent. A number of studies have
revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was …
revealed that the impact of C-reactive protein (CRP) on voriconazole pharmacokinetics was …
A physiologically based pharmacokinetic model of voriconazole integrating time-dependent inhibition of CYP3A4, genetic polymorphisms of CYP2C19 and …
Background Voriconazole, a first-line antifungal drug, exhibits nonlinear pharmacokinetics
(PK), together with large interindividual variability but a narrow therapeutic range, and …
(PK), together with large interindividual variability but a narrow therapeutic range, and …
[HTML][HTML] Prediction of plasma trough concentration of voriconazole in adult patients using machine learning
L Cheng, Y Zhao, Z Liang, X You, C Jia, X Liu… - European Journal of …, 2023 - Elsevier
Objective Plasma trough concentration of voriconazole (VCZ) was associated with its toxicity
and efficacy. However, the nonlinear pharmacokinetic characteristics of VCZ make it difficult …
and efficacy. However, the nonlinear pharmacokinetic characteristics of VCZ make it difficult …
Application of population pharmacokinetic analysis to characterize CYP2C19 mediated metabolic mechanism of voriconazole and support dose optimization
SC Li, SL Wu, WJ Gong, P Cao, X Chen… - Frontiers in …, 2022 - frontiersin.org
Purpose: The aims of this study were to establish a joint population pharmacokinetic model
for voriconazole and its N-oxide metabolite in immunocompromised patients, to determine …
for voriconazole and its N-oxide metabolite in immunocompromised patients, to determine …
Determination of a suitable voriconazole pharmacokinetic model for personalised dosing
DAJ McDougall, J Martin, EG Playford… - … of pharmacokinetics and …, 2016 - Springer
Abstract Model based personalised dosing (MBPD) is a sophisticated form of individualised
therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to …
therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to …
Evaluation of voriconazole CYP2C19 phenotype-guided dose adjustments by physiologically based pharmacokinetic modeling
P Zubiaur, LA Kneller, D Ochoa, G Mejía… - Clinical …, 2021 - Springer
Abstract Background and Objectives Controversy exists regarding dose adjustment in
patients treated with voriconazole due to the severity of the infections for which it is …
patients treated with voriconazole due to the severity of the infections for which it is …
Physiologically-based pharmacokinetic modeling-guided rational combination of tacrolimus and voriconazole in patients with different CYP3A5 and CYP2C19 alleles
F Gong, H Hu, Y Ouyang, ZZ Liao, Y Kong… - Toxicology and Applied …, 2023 - Elsevier
The drug-drug interactions (DDIs) between tacrolimus and voriconazole are highly variable
among individuals. We aimed to develop a physiologically based pharmacokinetic (PBPK) …
among individuals. We aimed to develop a physiologically based pharmacokinetic (PBPK) …
The impact of plasma protein binding characteristics and unbound concentration of voriconazole on its adverse drug reactions
ZQY Yuan, C Qiao, ZC Yang, L Yu, LN Sun… - Frontiers in …, 2020 - frontiersin.org
This study investigated voriconazole (VRC) unbound plasma concentration and its
relationship with adverse drug reactions (ADRs) in patients with malignant hematologic …
relationship with adverse drug reactions (ADRs) in patients with malignant hematologic …
Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach
Purpose Venetoclax, a targeted anticancer agent approved for the treatment of chronic
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …
lymphocytic leukemia and acute myeloid leukemia, is a substrate of cytochrome P450 (CYP) …